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Germany. Tel.: +49 30 450 553 373; fax: +49 30 450 553 916.setting [6]. Moreover, in HCV-infected kidney recipients, small
studies comparing the performance of non-invasive tests to liver
biopsies have shown inconsistent results [6]. Therefore, the util-
ity of such an expensive and laborious screening test to detect an
infection, which does not have any proven clinical consequences
is questionable.
In summary, data about the occult HCV infection in liver and/
or PBMCs despite negative HCV RNA in serum are conﬂicting.
Further well-designed longitudinal studies with serial analyses
for occult HCV infection from different geographic regions are
necessary to ﬁnally resolve this controversial issue.
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To the Editor:
In their review on liver graft quality assessment during preserva-
tion, Verhoeven et al. [1] point out a painful weakness that contin-
ues to hamper progress in the ﬁeld of liver transplantation. The
lack of validated markers that reliably predict graft quality and
function make comparison of trial results and meta-analysis
impossible. There is an urgent need for international guidelines
on appropriate end points to assess liver graft quality and
function and the authors refer to early allograft dysfunction
(EAD) as described by Olthoff et al. [2] as a starting point. Indeed,
EAD and particularly peak aspartate transaminase (AST), one of
the EAD components, are increasingly used as primary end
point in liver transplantation trials aimed to improve (early)
graft function (e.g. ISRCTN00167887; ISRCTN39731134). When
determining the peak of a marker, it is essential that kinetics of
this marker and especially the timing of the peak be precisely
known so that determination of that peak can be as accurate as
possible. Although AST is a well-recognizedmarker for hepatocyte
injury and used as a surrogate to assess preservation and ische-
mia-reperfusion injury, it is remarkable how little information is
available on the kinetics of AST post-reperfusion. It is generally
assumed that AST peaks within the ﬁrst 24 to 72 h post-reperfu-
sion [3,4]. However, considering AST is released quickly from
injured hepatocytes and is also quite rapidly cleared, it is not
unthinkable that a peak – particularly an early one – might be
missed if samples are not precisely taken. We therefore deter-
mined the evolution of AST early post-reperfusion, and the timing
of its peak. In addition, we compared the peak AST and its timing
in timed post-reperfusion samples vs. routinely taken samples
(that are usually used to determine peak AST in clinical trials).
We analyzed post-reperfusion AST values in 66 adult liver-
only recipients (60 years [48–67], 38 males) transplanted
between 11/2011 and 11/2013 who had consented for a prospec-
tive observational study on kidney injury during liver transplan-
tation (NCT01333319, approved by the Ethics Committee). In this
study, plasma samples were taken at the time of incision, 30 min,
2 h, 6 h, and 12 h post-reperfusion. Furthermore, recipients had
routine AST determinations with a ﬁrst AST sample ‘‘at arrival
on the intensive care unit’’ and daily morning measures until
postoperative day (POD) 5. The post-reperfusion timing of these
routinely taken samples was retrospectively determined from
the electronic patient records. AST was determined in the central
lab of the hospital (coloric method, Hitachi/Roche Modular P).
Continuous variables (median [inter quartile range]) were com-
pared between timed and routine samples by the Mann-Whitney
U test (SPSS version 19).
Donors were on average 57 (44–68) years old and livers
were transplanted with a cold ischemia time of 6 h (5–8) and1186 Journal of Hepatology 2014 vol. 61 j 1184–1191
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In clinical trials with peak AST as primary end point the time
window set to determine the AST peak is often wide (up to
POD7). Furthermore, the timing of the ﬁrst AST measurement is
rarely predeﬁned and mostly relies on routinely taken samples.
In this liver transplant cohort the majority of peak ASTs are
detected at 6 h post-reperfusion with a time window between
5 h and 11 h, considerably earlier that what is usually assumed.
Therefore, relying on routine blood samples to correctly measure
the AST peak should only be done if the ﬁrst routine sample
is taken in this time period. Subsequently, clinical trials using
peak AST as primary end point should clearly deﬁne the timing
of the ﬁrst blood sample and specify a time window for this
sample in the trial protocol. Based on the cohort presented
here, this could appropriately be deﬁned as a sample taken
anywhere between 5 h and 11 h after reperfusion and in our
experience will often be the ﬁrst blood sample taken in the
intensive care unit.
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Fig. 1. AST kinetics and timing of peak values after reperfusion. Panel (A)
shows the post-reperfusion kinetics of AST (mean ± SD) in 66 liver transplant
recipients early after reperfusion (from 30 min until 12 h) and daily until
postoperative day 5. Peak AST values measured in routinely taken or timed blood
samples are not different in this population (p = 0.71), panel (B). The timing of the
AST peak is shown in panel (C) and is also similar between routinely taken and
timed blood samples (p = 0.46).
JOURNAL OF HEPATOLOGYanastomotic times of 45 min (40–45). Indications for liver
transplantation were acute liver failure (n = 7), HCV/HBV cirrho-
sis (n = 12), cholestatic cirrhosis (n = 13), post-ethyl cirrhosis
(n = 14), NASH cirrhosis (n = 5), cryptogenic cirrhosis (n = 4)
retransplantation (n = 4) and others (n = 7). In 28 cases a simul-
taneous hepatocellular carcinoma was present, accounting for
the fact that the MELD score at time of transplantation was
low (13 [10–18]). Indeed, Eurotransplant awards ‘‘exceptional’
MELD points in case of hepatocellular carcinoma within
Milan criteria [5]. Eleven livers were donated after circulatory
death with a total warm ischemia time in the donor of
23 min (16–27).
The AST kinetics show that AST increases immediately after
reperfusion to peak at 6 h, after which there is a steady decrease
with values halved by POD1 (Fig. 1A). Both peak and timing of the
AST peak were similar between timed and routinely taken blood
samples in this study population (6 h [6–6] vs. 6 h [5–11]
p = 071; 948 IU/L [593–1508] vs. 908 IU/L [512–1146], p = 0.46;
respectively) with 90% of AST peaks detected in the ﬁrst 14 h
(Fig. 1B and C). E-mail address: ina.jochmans@uzleuven.be
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